Answers are grounded in this paper and cite their sources.
• This study tracked spleen size before and about a month after CAR-T therapy and compared the change with outcomes. • Patients who responded to treatment tended to have a larger early drop in spleen size than those who did not. • A bigger early shrinkage of the spleen was linked with longer time without disease worsening and longer survival. • The initial spleen size alone did not predict outcomes. • Whether the spleen was involved by lymphoma at the start did not change outcomes on its own, but combined with spleen shrinkage it helped sort patients’ risk. Chimeric antigen receptor T-cell (CART) therapy targeting CD19 is effective for relapsed/refractory (r/r) lymphoma. As part of the lymphatic system, the spleen might influence CART outcomes. We examined how spleen volume (SV) and its changes affect progression-free (PFS) and overall survival (OS). Patients with baseline (BL) and 30-day follow-up (FU1) (PET)/CT scans were included. Spleens were 3D-segmented, and volume change (SVC) from BL to FU1 was calculated. Treatment response, overall response rate, and PFS were evaluated by Lugano criteria. Among 68 patients, responders had a significantly greater SVC decrease from BL to FU1 than non-responders (p=0.001). Those with baseline splenic involvement (SI BL ) showed a smaller, non-significant SVC BL to FU1 decrease (p=0.056). Survival analysis showed significant differences in OS (167 vs. 390 days, p=0.040) and PFS (79 vs. 327 days, p=0.008) based on median SVC BL to FU1 . In combination with SI BL , SVC was significantly associated with PFS (p=0.049), but not OS. This study demonstrated that the early change in SV is associated with PFS and OS, regardless of splenic involvement and should be explored as a potential novel dynamic biomarker in the context of lymphoma patients receiving CART.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: